Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 22
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Gong, C Fujino, K Monteiro, L J Gomes, A R Drost, R Davidson-Smith, H Takeda, S Khoo, U S Jonkers, J Sproul, D and Lam, E W-F 2015. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene, Vol. 34, Issue. 39, p. 5012.


    Jayavelu, Naresh Doni Aasgaard, Lasse S. and Bar, Nadav 2015. Iterative sub-network component analysis enables reconstruction of large scale genetic networks. BMC Bioinformatics, Vol. 16, Issue. 1,


    Karagoz, Kubra Sinha, Raghu and Arga, Kazim Yalcin 2015. Triple Negative Breast Cancer: A Multi-Omics Network Discovery Strategy for Candidate Targets and Driving Pathways. OMICS: A Journal of Integrative Biology, Vol. 19, Issue. 2, p. 115.


    Mehmeti, Meliha Allaoui, Roni Bergenfelz, Caroline Saal, Lao H. Ethier, Stephen P. Johansson, Martin E. Jirström, Karin and Leandersson, Karin 2015. Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Research, Vol. 17, Issue. 1,


    Perkins, Susan M. Bales, Casey Vladislav, Tudor Althouse, Sandra Miller, Kathy D. Sandusky, George Badve, Sunil and Nakshatri, Harikrishna 2015. TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. Breast Cancer Research and Treatment, Vol. 152, Issue. 3, p. 519.


    Xu, Chenpu Wei, Qun Guo, Jufeng Zhou, Ji Chun Mei, Jin Jiang, Zhi Nong Shen, Jian Guo and Wang, Lin Bo 2015. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients. Annals of Surgical Oncology, Vol. 22, Issue. 6, p. 2034.


    Zhao, Yongbing and Li, Zhaoyu 2015. Interplay of estrogen receptors and FOXA factors in the liver cancer. Molecular and Cellular Endocrinology, Vol. 418, p. 334.


    Aung, Khin Moh Moh New, Siu Yee Hong, Shuzhen Sutarlie, Laura Lim, Michelle Gek Liang Tan, Si Kee Cheung, Edwin and Su, Xiaodi 2014. Studying forkhead box protein A1–DNA interaction and ligand inhibition using gold nanoparticles, electrophoretic mobility shift assay, and fluorescence anisotropy. Analytical Biochemistry, Vol. 448, p. 95.


    Khushi, Matloob Clarke, Christine L. and Graham, J. Dinny 2014. Bioinformatic analysis of cis-regulatory interactions between progesterone and estrogen receptors in breast cancer. PeerJ, Vol. 2, p. e654.


    Kong, S. L. Li, G. Loh, S. L. Sung, W.-K. and Liu, E. T. 2014. Cellular reprogramming by the conjoint action of ER , FOXA1, and GATA3 to a ligand-inducible growth state. Molecular Systems Biology, Vol. 7, Issue. 1, p. 526.


    Liu, Yawei Carlsson, Robert Comabella, Manuel Wang, JunYang Kosicki, Michael Carrion, Belinda Hasan, Maruf Wu, Xudong Montalban, Xavier Dziegiel, Morten Hanefeld Sellebjerg, Finn Sørensen, Per Soelberg Helin, Kristian and Issazadeh-Navikas, Shohreh 2014. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nature Medicine, Vol. 20, Issue. 3, p. 272.


    Fiorito, Elisa Katika, Madhumohan R. and Hurtado, Antoni 2013. Cooperating transcription factors mediate the function of estrogen receptor. Chromosoma, Vol. 122, Issue. 1-2, p. 1.


    Ivanov, S V Panaccione, A Nonaka, D Prasad, M L Boyd, K L Brown, B Guo, Y Sewell, A and Yarbrough, W G 2013. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. British Journal of Cancer, Vol. 109, Issue. 2, p. 444.


    Meyer, Kerstin B. O’Reilly, Martin Michailidou, Kyriaki Carlebur, Saskia Edwards, Stacey L. French, Juliet D. Prathalingham, Radhika Dennis, Joe Bolla, Manjeet K. Wang, Qin de Santiago, Ines Hopper, John L. Tsimiklis, Helen Apicella, Carmel Southey, Melissa C. Schmidt, Marjanka K. Broeks, Annegien Van ’t Veer, Laura J. Hogervorst, Frans B. Muir, Kenneth Lophatananon, Artitaya Stewart-Brown, Sarah Siriwanarangsan, Pornthep Fasching, Peter A. Lux, Michael P. Ekici, Arif B. Beckmann, Matthias W. Peto, Julian dos Santos Silva, Isabel Fletcher, Olivia Johnson, Nichola Sawyer, Elinor J. Tomlinson, Ian Kerin, Michael J. Miller, Nicola Marme, Federick Schneeweiss, Andreas Sohn, Christof Burwinkel, Barbara Guénel, Pascal Truong, Thérèse Laurent-Puig, Pierre Menegaux, Florence Bojesen, Stig E. Nordestgaard, Børge G. Nielsen, Sune F. Flyger, Henrik Milne, Roger L. Zamora, M. Pilar Arias, Jose I. Benitez, Javier Neuhausen, Susan Anton-Culver, Hoda Ziogas, Argyrios Dur, Christina C. Brenner, Hermann Müller, Heiko Arndt, Volker Stegmaier, Christa Meindl, Alfons Schmutzler, Rita K. Engel, Christoph Ditsch, Nina Brauch, Hiltrud Brüning, Thomas Ko, Yon-Dschun Nevanlinna, Heli Muranen, Taru A. Aittomäki, Kristiina Blomqvist, Carl Matsuo, Keitaro Ito, Hidemi Iwata, Hiroji Yatabe, Yasushi Dörk, Thilo Helbig, Sonja Bogdanova, Natalia V. Lindblom, Annika Margolin, Sara Mannermaa, Arto Kataja, Vesa Kosma, Veli-Matti Hartikainen, Jaana M. Chenevix-Trench, Georgia Wu, Anna H. Tseng, Chiu-chen Van Den Berg, David Stram, Daniel O. Lambrechts, Diether Thienpont, Bernard Christiaens, Marie-Rose Smeets, Ann Chang-Claude, Jenny Rudolph, Anja Seibold, Petra Flesch-Janys, Dieter Radice, Paolo Peterlongo, Paolo Bonanni, Bernardo Bernard, Loris Couch, Fergus J. Olson, Janet E. Wang, Xianshu Purrington, Kristen Giles, Graham G. Severi, Gianluca Baglietto, Laura McLean, Catriona Haiman, Christopher A. Henderson, Brian E. Schumacher, Fredrick Le Marchand, Loic Simard, Jacques Goldberg, Mark S. Labrèche, France Dumont, Martine Teo, Soo-Hwang Yip, Cheng-Har Phuah, Sze-Yee Kristensen, Vessela Grenaker Alnæs, Grethe Børresen-Dale, Anne-Lise Zheng, Wei Deming-Halverson, Sandra Shrubsole, Martha Long, Jirong Winqvist, Robert Pylkäs, Katri Jukkola-Vuorinen, Arja Kauppila, Saila Andrulis, Irene L. Knight, Julia A. Glendon, Gord Tchatchou, Sandrine Devilee, Peter Tollenaar, Robert A.E.M. Seynaeve, Caroline M. García-Closas, Montserrat Figueroa, Jonine Chanock, Stephen J. Lissowska, Jolanta Czene, Kamila Darabi, Hartef Eriksson, Kimael Hooning, Maartje J. Martens, John W.M. van den Ouweland, Ans M.W. van Deurzen, Carolien H.M. Hall, Per Li, Jingmei Liu, Jianjun Humphreys, Keith Shu, Xiao-Ou Lu, Wei Gao, Yu-Tang Cai, Hui Cox, Angela Reed, Malcolm W.R. Blot, William Signorello, Lisa B. Cai, Qiuyin Pharoah, Paul D.P. Ghoussaini, Maya Harrington, Patricia Tyrer, Jonathan Kang, Daehee Choi, Ji-Yeob Park, Sue K. Noh, Dong-Young Hartman, Mikael Hui, Miao Lim, Wei-Yen Buhari, Shaik A. Hamann, Ute Försti, Asta Rüdiger, Thomas Ulmer, Hans-Ulrich Jakubowska, Anna Lubinski, Jan Jaworska, Katarzyna Durda, Katarzyna Sangrajrang, Suleeporn Gaborieau, Valerie Brennan, Paul McKay, James Vachon, Celine Slager, Susan Fostira, Florentia Pilarski, Robert Shen, Chen-Yang Hsiung, Chia-Ni Wu, Pei-Ei Hou, Ming-Feng Swerdlow, Anthony Ashworth, Alan Orr, Nick Schoemaker, Minouk J. Ponder, Bruce A.J. Dunning, Alison M. and Easton, Douglas F. 2013. Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. The American Journal of Human Genetics, Vol. 93, Issue. 6, p. 1046.


    Montani, Matteo Herrmanns, Thomas Müntener, Michael Wild, Peter Sulser, Tullio and Kristiansen, Glen 2013. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Archiv, Vol. 462, Issue. 4, p. 437.


    Rodríguez-Cruz, Maricela Salazar, Emmanuel and Ramírez-Salcedo, Jorge 2013. Identification of Putative Ortholog Gene Blocks Involved in Gestant and Lactating Mammary Gland Development: A Rodent Cross-Species Microarray Transcriptomics Approach. International Journal of Genomics, Vol. 2013, p. 1.


    Wang, Liang Qin, Huaizhou Li, Lihong Feng, Fuqiang Ji, Peigang Zhang, Jingyu Li, Gang Zhao, Zhenwei and Gao, Guodong 2013. Forkhead-box A1 transcription factor is a novel adverse prognosis marker in human glioma. Journal of Clinical Neuroscience, Vol. 20, Issue. 5, p. 654.


    Guttilla, Irene K. Adams, Brian D. and White, Bruce A. 2012. ERα, microRNAs, and the epithelial–mesenchymal transition in breast cancer. Trends in Endocrinology & Metabolism, Vol. 23, Issue. 2, p. 73.


    Haughian, J. M. Pinto, M. P. Harrell, J. C. Bliesner, B. S. Joensuu, K. M. Dye, W. W. Sartorius, C. A. Tan, A. C. Heikkila, P. Perou, C. M. and Horwitz, K. B. 2012. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proceedings of the National Academy of Sciences, Vol. 109, Issue. 8, p. 2742.


    Naderi, Ali Meyer, Michelle and Dowhan, Dennis H. 2012. Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer. Neoplasia, Vol. 14, Issue. 4, p. 283.


    ×
  • Expert Reviews in Molecular Medicine, Volume 11
  • 2009, e8

FOXA1 in breast cancer

  • Harikrishna Nakshatri (a1) and Sunil Badve (a2)
  • DOI: http://dx.doi.org/10.1017/S1462399409001008
  • Published online: 01 March 2009
Abstract

Breast cancer is a heterogeneous disease and classification is important for clinical management. At least five subtypes can be identified based on unique gene expression patterns; this subtype classification is distinct from the histopathological classification. The transcription factor network(s) required for the specific gene expression signature in each of these subtypes is currently being elucidated. The transcription factor network composed of the oestrogen (estrogen) receptor α (ERα), FOXA1 and GATA3 may control the gene expression pattern in luminal subtype A breast cancers. Breast cancers that are dependent on this network correspond to well-differentiated and hormone-therapy-responsive tumours with good prognosis. In this review, we discuss the interplay between these transcription factors with a particular emphasis on FOXA1 structure and function, and its ability to control ERα function. Additionally, we discuss modulators of FOXA1 function, ERα–FOXA1–GATA3 downstream targets, and potential therapeutic agents that may increase differentiation through FOXA1.

Copyright
Corresponding author
*Corresponding author: Harikrishna Nakshatri, R4-202, Indiana University School of Medicine, 1044 West Walnut Street, Indianapolis, IN 46202, USA. Tel: +1 317 278 2238; Fax: +1 317 274 0396; E-mail: hnakshat@iupui.edu
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1J.E. Visvader and G.J. Lindeman (2006) Mammary stem cells and mammopoiesis. Cancer Research 66, 9798-9801

2A. Raouf (2008) Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3, 109-118

3R. Villadsen (2005) In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. APMIS 113, 903-921

4J.S. Carroll (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43

5J. Laganiere (2005) From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proceedings of the National Academy of Sciences of the United States of America 102, 11651-11656

6J. Eeckhoute (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Research 67, 6477-6483

7R.H. Costa , D.R. Grayson and J.E. Darnell Jr (1989) Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Molecular and Cellular Biology 9, 1415-1425

8E. Lai (1990) HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally. Genes and Development 4, 1427-1436

9E. Lai (1991) Hepatocyte nuclear factor 3 alpha belongs to a gene family in mammals that is homologous to the Drosophila homeotic gene fork head. Genes and Development 5, 416-427

10K.H. Kaestner (2000) The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends in Endocrinology and Metabolism 11, 281-285

11R.J. Matusik (2008) Prostate epithelial cell fate. Differentiation 76, 682-698

12S.H. Panowski (2007) PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature 447, 550-555

13L.A. Cirillo (2002) Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Molecular Cell 9, 279-289

14K.L. Clark (1993) Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364, 412-420

15L.A. Cirillo and K.S. Zaret (2007) Specific interactions of the wing domains of FOXA1 transcription factor with DNA. Journal of Molecular Biology 366, 720-724

16X. Qian and R.H. Costa (1995) Analysis of hepatocyte nuclear factor-3 beta protein domains required for transcriptional activation and nuclear targeting. Nucleic Acids Research 23, 1184-1191

17G. Achatz (1997) Functional domains of the human orphan receptor ARP-1/COUP-TFII involved in active repression and transrepression. Molecular and Cellular Biology 17, 4914-4932

18J.Y. Kim (2004) Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3/Foxa transactivation via inhibition of its DNA binding. Molecular Endocrinology 18, 2880-2894

19N. Gao (2003) The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Molecular Endocrinology 17, 1484-1507

20P. Minoo (2007) Physical and functional interactions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lung epithelial cells. Molecular and Cellular Biology 27, 2155-2165

21P. Minoo (2008) SMAD3 prevents binding of NKX2.1 and FOXA1 to the SpB promoter through its MH1 and MH2 domains. Nucleic Acids Research 36, 179-188

22T. Sekiya and K.S. Zaret (2007) Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo. Molecular Cell 28, 291-303

23T. Kouzarides (2007) Chromatin modifications and their function. Cell 128, 693-705

24M. Lupien (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970

25B. Li , M. Carey and J.L. Workman (2007) The role of chromatin during transcription. Cell 128, 707-719

26R.J. Klose (2007) The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128, 889-900

27J. Christensen (2007) RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 128, 1063-1076

28S. Iwase (2007) The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 128, 1077-1088

29K. Yamane (2007) PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Molecular Cell 25, 801-812

30H. Kouros-Mehr (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055

31M.L. Asselin-Labat (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology 9, 201-209

32S. Badve (2007) FOXA1 expression in breast cancer correlation with luminal subtype A and survival. Clinical Cancer Research 13, 4415-4421

34C.L. Varley (2008) FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation. Cell Death and Differentiation 16, 103-114

35A. Jacob , S. Budhiraja and R.R. Reichel (1999) The HNF-3alpha transcription factor is a primary target for retinoic acid action. Experimental Cell Research 250, 1-9

36A.S. Doane (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008

37A. Naderi and L. Hughes-Davies (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10, 542-548

38D. Sinner (2004) Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development 131, 3069-3080

39B. Schuettengruber (2007) Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745

40A.P. Bracken (2006) Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes and Development 20, 1123-1136

41T.I. Lee (2006) Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125, 301-313

42J. Schneider (2006) Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. International Journal of Cancer 119, 2974-2979

43B.J. Wilson and V. Giguere (2008) Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Molecular Cancer 7, 49

44J. Eeckhoute (2006) A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes and Development 20, 2513-2526

45J.L. Su (2007) Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. Journal of Biological Chemistry 282, 19385-19398

46N. Jonckheere (2007) The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells. Journal of Biological Chemistry 282, 22638-22650

47N. Gao (2005) Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132, 3431-3443

48K.S. Korkmaz (2000) Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens. Gene 260, 25-36

49T. Kusumegi (2004) BMP7/ActRIIB regulates estrogen-dependent apoptosis: new biomarkers for environmental estrogens. Journal of Biochemical and Molecular Toxicology 18, 1-11

50J.T. Dong (2001) Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer and Metastasis Reviews 20, 173-193

51K. Holmes (2008) Nkx3–1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Cancer Research 68, 7380-7385

52E.P. Gelmann , C. Bowen and L. Bubendorf (2003) Expression of NKX3.1 in normal and malignant tissues. Prostate 55, 111-117

53B.C. Pestalozzi (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. Journal of Clinical Oncology 26, 3006-3014

54H.O. Habashy (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. European Journal of Cancer 44, 1541-1551

55N. Bretschneider (2008) Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner. Cancer Research 68, 106-114

56J. Frasor (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144, 4562-4574

57I. Ben-Porath (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics 40, 499-507

58E.A. Williamson (2006) BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). Oncogene 25, 1391-1399

60C.M. Perou (2000) Molecular portraits of human breast tumours. Nature 406, 747-752

61S. Badve and H. Nakshatri (2009) Oestrogen receptor-positive breast cancer: towards bridging histopathologic and molecular classifications. Journal of Clinical Pathology 62, 6-12

62L.A. Carey (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. The Journal of the American Medical Association 295, 2492-2502

63M.A. Thorat (2007) FOXA1 expression in breast cancer is associated with Luminal subtype and good prognosis. Journal of Clinical Pathology 61, 327–32

64N. Yamaguchi (2008) FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochemical and Biophysical Research Communications 365, 711-717

65A.K. Conlin and A.D. Seidman (2007) Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Molecular Diagnosis and Therapy 11, 355-360

66S. Paik (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24, 3726-3734

67P. Bhat-Nakshatri (2008) AKT alters genome-wide estrogen receptor {alpha} binding and impacts estrogen signaling in breast cancer. Molecular and Cellular Biology 28, 7487-7503

68A. Sayeed (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Research 67, 7746-7755

70C. Sotiriou (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 98, 262-272

71S. Loi (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 25, 1239-1246

72I. Wolf (2007) FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. International Journal of Cancer 120, 1013-1022

74U. Veronesi (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Annals of Oncology 17, 1065-1071

75X. Qian (1995) Decreased expression of hepatocyte nuclear factor 3 alpha during the acute-phase response influences transthyretin gene transcription. Molecular and Cellular Biology 15, 1364-1376

C. Sotiriou and M.J. Piccart (2007) Taking gene expression profiling to the clinic; when will molecular signatures become relevant to patient care? Nature Reviews Cancer 7, 545-553

F. Andre and L. Pusztai (2006) Molecular classification of breast cancer; implications for selection of adjuvant chemotherapy. Nature Clinical Practice Oncology 3, 621-632

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×